natgillin/translations-raw huggingface dataset:
The compound of claim 3, wherein the pharmaceutically acceptable salt is selected from the group consisting of acetate, ascorbate, benzoate, benzenesulfonate, bisulfate, borate, butyrate, citrate, camphorate, camphorsulfonate, fumarate, hydrochloride, hydrobromide, hydroiodide, lactate, maleate, methanesulfonate, naphthalenesulfonate, nitrate, oxalate, phosphate, propionate, salicylate, succinate, sulfate, tartarate, thiocyanate, and toluenesulfonate. 
Spoj prema patentnom zahtjevu 3, naznačen time što je farmaceutski prihvatljiva sol izabrana iz grupe koja se sastoji od acetata, askorbata, benzoata, benzensulfonata, bisulfata, borata, butirata, citrata, kamforata, kamforsulfonata, fumarata, hidroklorida, hidrobromida, hidrojodida, laktata, maleata, metansulfonata, naftalensulfonata, nitrata, oksalata, fosfata, propionata, salicilata, sukcinata, sulfata, tartarata, tiocijanata i toluensulfonata.
Preferably the tablet comprises croscarmellose sodium as disintegrant. 
Poželjno tableta sadržava kroskarameloza natrij kao sredstvo za raspadanje.
A host cell comprising the vector of claim 6. A method for the preparation of an antibody molecule of any one of claims 1 to 4 comprising culturing the host cell of claim 7 under conditions that allow synthesis of said antibody molecule and recovering said antibody molecule from said culture. 
Postupak za pripravljanje molekule protutijela prema bilo kojem zahtjevu od 1 do 4, naznačen time, da obuhvaća kultiviranje stanice domaćina prema zahtjevu 7 pod uvjetima koji dopuštaju sintezu spomenute molekule protutijela i oporavljanje spomenute molekule protutijela iz tog uzgoja.
The compound of Claim 9 selected from the group consisting of: 
Spoj prema zahtjevu 9 naznačen time da je odabran iz skupine koja sadrži:
n is an integer of 0, 1, or 2, X represents -S(O)m- or a single bond, wherein m is an integer of 0, 1, or 2, and R represents hydrogen or is a residue Ra, which residue Ra is selected from the group consisting of: 
"Oh u naznačen time, da nje cijeli broj od 0, 1 ili 2, X predstavlja -S(O),-, (C=0)- ili jednostruku vezu, pri čemu m je cijeli broj 0, 1 ili 2,1 R predstavlja vodik ili je ostatak R*, koji ostatak R* je odabran iz skupine koju čine:
In an embodiment of the methods disclosed, the pain is the patient-reported total injection pain rating on a visual analogue scale (VAS) occurring immediately after injection. 
Jedinična doza prema patentnom zahtjevu 7, naznačena time, da bol jest ukupna ocjena boli od injekcije, pretrpljene neposredno nakon injekcije, koju pacijent ocjenjuje na vizualnoj analognoj skali (VAS - Visual Analogue Scale).
Transmission of the images acquired to a receiving device (10) installed on the train in transit towards the said crossing point (2); 
- prijenos slika dobivenih na prijemni uređaj (10) instaliran na vlaku u prolazu prema navedenom mjestu prijelaza
Thus the base unit 3 comprise a housing with an outer wall 16, means for attachment to the outlet end 9 of a collapsible container 2, and means for cooperating with a base part 5. 
Tako, dakle, osnovna jedinica 3 obuhvaća kućište s vanjskom stijenkom 16, sredstvo za spajanje na izlazni kraj 9 sklopivog spremnika 2, i sredstvo koje djeluje zajedno s osnovnim dijelom S.
Following this, the plate-shaped composite structure containing the solidified filling medium is cut up by sawing it with a very high speed diamond circular saw along the lines 6, or is provided with the grooves 6' as shown in Figure 2c. 
Nakon toga se pločastu kompozitnu strukturu, koja sadrži skrutnuto punilo, prereže uzduž linija 6 piljenjem s kružnom dijamantnom pilom vrlo velike brzine, ili se naprave brazde 6', kako je prikazano na slici 2c.
Separating at least a portion of the soaked liquid from the second soaked biomass to create a soaked liquid stream comprised of suspended solids, monomeric sugar, oligomeric sugars, acetic acid, and furfural and a second solid stream; wherein the second solid stream comprises the second soaked biomass, Separating at least a portion of the soaked liquid from the suspended solids of the soaked liquid stream comprising monomeric sugars, oligomeric sugars, acetic acid, and furfural, 
E) odvajanja u najmanju ruku dijela namočene tekućine od suspendiranih krutina iz struje namočene tekućine, koje su monomerni šećeri, oligomerni šećeri, octena kiselina 1 furfural, F) filtriranja u najmanju ruku dijela octene kiseline iz u najmanju ruku dijela namočene tekućine kako bi se dobilo permeat i retentat, gdje se filtriranje sastoji u nanofiltriranju.
A light source as claimed in claim 16, wherein the void is small in comparison with a distance within the body from the Faraday cage at one side or end and to the opposite side or end and the re-entrant is along side or in line with the void. 
Svjetlosni izvor u skladu s patentnim zahtjevom 11, naznačen time, da je debljina stijenke plazmenc retorto mala u odnosu na udaljenost unutar plazmene retorte od Faradayevog kaveza na jednoj strani ili kraju do druge strane ili kraja.
A further aspect of the invention relates to the use of a 1-amino-alkylcyclohexane derivative (e.g., neramexane or a pharmaceutically acceptable salt thereof such as neramexane mesylate) for the manufacture of a medicament for the treatment of an inner ear disorder, e.g. 
Nerameksan ili njegova farmaceutski prihvatljiva sol za uporabu kod liječenja ili prevencije tinitusa, naznačen time da se liječenje provodi unutar tri do dvanaest mjeseci od početka tinitusa (subakutni tinitus).
Caution this moderate exotherm requires cooling with an external ice bath. 
Potreban je oprez, jer ova umjerena egzotermna reakcija zahtjeva hlađenje sa vanjskom ledenom kupkom.
Representative examples of compound of Formula (I) are shown below in TABLE A. 
Tipični primjeri spoja Formule (I) su prikazani ispod u TABELI A. HR P20060286 T3
In these especially preferred embodiments, the plant strengtheners according to the invention comprise the dimethyl sulfoxide preferably in a concentration of from 50 to 350 g/l, in particular in a concentration of from 100 to 300 g/l, and the benzyl alcohol in a concentration of from 50 to 350 g/l, in particular in a concentration of from 100 to 300 g/l. 
Osnaživač bilja prema bilo kojem od prethodnih zahtjeva, naznačen time da sadrži: a) 50 do 500 g/l komponente A; b) 50 do 400 g/l komponente B; ili c) 5 do 50 g/l komponente C, izračunate kao element born; i ako je prikladno, d) 50 do 250 g/l komponente D i/ili e)
Alternatively, a liposomal formulation is prepared by the method of US Published Application No. 
Alternativno, liposomalna formulacija pripravljena je metodom iz US objavljene prijave Br.
The solution is transferred to a 10 L glass vessel and the mass is slowly cooled to 0-5°C for about 1 hour. 
Otopina se prenese u tikvicu od 101i masa se polagano hladi do 0-5 "€ tijekom 1 sata.
A cloning or expression vector comprising one or more isolated polynucleotide sequences according to claim 12 or claim 13. 
Vektor kloniranja ili ekspresije, naznačen time, da on obuhvaća jednu ili više izoliranih polinukleotidnih sekvenci u skladu sa zahtjevom 12 ili zahtjevom 13.
The compound, or a pharmaceutically acceptable salt thereof, of claim 4, wherein Z is -SO2R21. 
Spoj ili njegova farmaceutski prihvatljiva sol u skladu s patentnim zahtjevom 4, naznačen time, da Z je -SO2R21.
They are mainly soluble oligo- and polysaccharides that are non digestible, which means that they are neither digested by human enzymes of the GI tract nor absorbed in the upper digestive tract. 
To su uglavnom topljivi oligosaharidi i polisaharidi koji nisu probavljivi, što znači da ih enzimi u čovječjem GI sustavu nikada ne razgrade, niti se ne apsorbiraju u gornjim dijelovima probavnog sustava.
The treatment agent for the relapsing-remitting or secondary progressive multiple sclerosis at the time of relapse according to claim 9, wherein the benzopyran derivative is N-[7-[(methylsulfonyl)amino]-4-oxo-6-phenoxy-4H-1-benzopyran-3-yl]formamide. 
Sredstvo za liječenje namijenjeno uporabi u skladu s patentnim zahtjevom 5, naznačeno time, da je derivat benzopirana N-[7-[(metilsulfonil)amino]-4-okso-6-fenoksi-4H-1-benzopiran-3-il]formamid.
emulsion-forming means provided in said washing chamber for forming an emulsion of fluid components by mechanical stirring, wherein said emulsion-forming means comprise unattached stirring members (104) for increasing the emulsion of liquid components when the washing and separating container (1) is subjected to mechanical stirring, a force equal to the force imparted by manual action being sufficient to create said emulsion; and 
Uređaj kao što je naveden u patentnom zahtjevu 2, naznačen time da se navedena sredstva za formiranje emulzije sastoje od najmanje jednog elementa za miješanje (104) za povećanje emulzije tekućih komponenti kada je kontejner (1) za pranje i odvajanje podvrgnut mehaničkom ili manualnom miješanju, pri čemu je sila jednaka onoj koja je korištena pri manualnoj radnji dovoljna da se stvori navedena emulzija.
The humanized CD37-specific binding protein or the CD20-specific binding protein or the article of manufacture for use in treating a B-cell cancer or an autoimmune disease of any one of claims 8 or 9, wherein: 
Humanizirani protein koji se specifično veže na CD37, ili protein koji se specifično veže na CD20, ili proizvodni artikl za upotrebu u liječenju karcinoma B-stanica ili autoimune bolesti navedeni u patentnom zahtjevu 8 ili 9, pri čemu:
In an embodiment, the aqueous formulation comprises 90 µg/mL zinc, 2.7 mg/mL m-cresol and 20 mg/ml glycerol 85%, in particular, the formulations comprises 90 µg/mL zinc, 2.7 mg/mL m-cresol, 20µg/mL polysorbate 20 and 20 mg/mL glycerol 85%. 
Vodena formulacija u skladu s patentnim zahtjevom 6, naznačena time što sadrži 90 mg/ml cinka, 2,7 mg/ml m- krezola i 20 mg/ml 85%-tnog glicerola. Vodena formulacija u skladu s patentnim zahtjevom 6, naznačena time što sadrži 90 mg/ml cinka, 2,7 mg/ml m- krezola, 20 mg/ml polisorbat 20 i 20 mg/ml $5%-tnog glicerola.
reacting a compound of formula (2): or a pharmaceutically acceptable salt thereof, with a Grignard reagent of formula (3): under suitable conditions to form an intermediate product; and 
O ili njegove farmaceutski prihvatljive soli, s Grignardovim reagensom formule (3): ugo u uvjetima pogodnim za dobivanje međuprodukta; i reakciji međuprodukta iz a) sa spojem formule (1):
The pharmaceutical composition of claim 1, wherein the aqueous buffer provides a pH to the composition of about 6. 
Farmaceutska kompozicija bilo kojeg od patentnih zahtjeva 3-6, gdje farmaceutska kompozicija ima pH od oko 4.
A compound of formula 1 according to any one of claims 1 to 8 for use as a medicament for the treatment of obesity and related inflammation, insulin resistance, diabetes, fatty liver and liver steatosis. 
Spoj formule 1 u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačen time, da se upotrebljava kao lijek za liječenje pretilosti i upala koje su povezane s time, otpornosti na inzulin, dijabetesa, masne jetre i jetrene steatoze.
Method as in claim 6 or 7, characterized in that during said detection it provides to detect an arc current (IA) and an arc voltage (UA). 
Postupak prema patentnom zahtjevu 10 ili 11, naznačen time što navedene detekcije omogućuje detektiranje struje luka (IA) i napona luka (UA).
represents a benzene ring or a naphthalene ring; the rings being optionally substituted by 1 to 4 substituents selected from a C1-6 alkyl group, C3-7 cycloalkyl group, a C3-7 cycloalkyl-C1-6 alkyl group, a halogen atom, a C1-2 perhalogenated alkyl group, a C1-3 halogenated alkyl group, a hydroxyl group, a C1-6 alkoxy group optionally substituted by a C3-5 cycloalkyl group, a C1-2 perhalogenated alkoxy group, a C1-6 alkylsulfonyl group, a nitro, a cyano, an amino, a C1-6 monoalkylamino group or a C2-12 dialkylamino group, an acetoxy group or an aminosulfonyl group; represents a hydrogen atom, a C1-6 alkyl group or a halogen atom; 
R2 predstavlja benzenski prsten ili naftalenski prsten, gdje su navedeni prsteni izborno supstituirani s 1 do 4 supstituenta, koje se bira između C1.4 alkilne skupine, C;.7 cikloalkilne skupine, C3.7 cikloalkil-C,.4 alkilne skupine, atoma halogena, C,.> perhalogenirane alkilne skupine, C;., halogenirane alkilne skupine, hidroksilne skupine, C;.4 alkoksi skupine, izborno supstituirane s C;_.5 cikloalkilnom skupinom, C1.2 perhalogeniranom alkoksi skupinom, C1.4 alkilsulfonilnom skupinom, nitro, cijano, amino, C1.g monoalkilamino skupinom, C212 dialkilamino skupinom, acetoksi skupinom ili aminosulfonilnom skupinom; R3 predstavlja atom vodika, C;.4 alkilnu skupinu ili atom halogena; R4 predstavlja atom vodika ili C,.4 alkilnu skupinu;
that the mobile communication technology is one out of the following: 
Sustav prema jednom od zahtjeva 7 do 9, pri čemu je mobilna komunikacijska tehnologija jedna od slijedećih:
There are multiple studies that have assessed the anorexic effect of the Sanofi CB-1 antagonist, SR-141716 (Rowland, et. 
Postoje raznovrsne studije koje su procjenjivale učinak Sanofijeva CB-I antagonista na anoreksiju, SR-141716 (Rowland, et.
A pharmaceutical formulation for use in the treatment of respiratory disease according to any of Claims 1 to 6 in a form suitable for administration by oral or nasal inhalation. 
Farmaceutska formulacija namijenjena upotrebi u liječenju bolesti dišnog sustava u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačena time što je u obliku pogodnom za primjenu oralnom ili nazalnom inhalacijom.
The compound or pharmacologically acceptable salt thereof according to claim 2, wherein is a hydrogen atom; and is a 3,4,5,6-tetrahydro-2H-3-pyranyl group, a 3,4,5,6-tetrahydro-2H-4-pyranyl group, or a 3-tetrahydrofuranyl group. 
Spoj ili njegova farmakološki prihvatljiva sol prema zahtjevu 2, naznačen time da R3 je atom vodika; i R5 je skupina 3,4,5,6-tetrahidro-2H-3-piranil, skupina 3,4,5,6-tetrahidro-2H-4-piranil, ili skupina 3-tetrahidrofuranil.
The solids flow control system of claim 14, wherein the system includes a plurality of transport pipes, and each transport pipe is in communication with the plurality of solids control valves. An active grid solids distributor comprising: 
Sustav regulacije protoka krutih tvari prema zahtjevu 10, naznačen time da sustav sadrži mnoštvo transportnih cijevi (120) i pri čemu je svaka transportna cijev (120) u komunikaciji s mnoštvom regulacijskih ventila za krute tvari.
A compound according to claim 19, or a pharmaceutically acceptable salt thereof, wherein R2 and R3 form, together with the N atom to which they are bound, a saturated heterocyclic group selected from (a) or (b). 
Spoj u skladu s patentnim zahtjevom 12, naznačen time, da R2 i R3 tvore, zajedno s N atomom za kojeg su vezani, zasićenu heterocikličku skupinu odabranu od (a) i (b). 14.
Device according to claim 14, where a fluid supply valve is located between the system valves and adapted to allow inflow of a fluid when the system valves and the release valve are closed. 
- gdje se ventil za dovod fluida nalazi između sustavnih ventila 1 prilagođen je da omogući dotok fluida kada su sustavni ventili i ispusni ventil zatvoreni;
The composition of any one of claims 1 to 9 for use in a method of selectively binding and inhibiting an exogenously administered factor Xa inhibitor in a subject undergoing anticoagulant therapy. 
Pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1 do 6, ili polipeptid prema bilo kojem od patentnih zahtjeva 7-12 naznačen time što se upotrebljava u postupku selektivnog vezanja i inhibiranja egzogeno primijenjenog inhibitora faktora Xa kod subjekta koji je podvrgnut antikoagulacijskoj terapiji.
Administration of the glutamate/NMDA antagonist phencyclidine (PCP) has been considered to provide a better model of schizophrenia in that it can induce both negative symptoms as well as the positive symptoms associated with amphetamine psychosis (J. D. Jentsch and R. H. Roth, Neuropsychopharmacology (1999) 20(3): 201-225). 
Smatralo se da primjena glutamat/NMDA antagonista fenciklidina (PCP) daje bolji model šizofrenije u tome što potiče negativne simptome i pozitivne simptome povezane s amfetaminskom psihozom (J. D. Jentsch 1 R. H. Roth, Neuropsychopharmacology (1999) 20(3): 201-225).
WO-A-04/08317 and WO-A-02/064439 respectively disclose a vial closure of monolithic construction and of two-part, i.e. having a base portion, and a re-sealable portion made of a fusible material, construction. 
WO-A-04/08317 odnosno WO-A-02/064439 otkrivaju zatvarač za bočicu cjelovite izvedbe iz jednog komada, odnosno izvedbe iz dva komada, to jest koji imaju temeljni dio i dio koji se može nepropusno spojiti i koji je načinjen od materijala koji se može lijepiti.
At the end of a run carried out with non-recycled Fibra-Cel® disks, the entire system was emptied of all liquid and then refilled with hot Water For Injection (WFI). 
Na kraju runde koja je provođena s ne-recikliranim diskovima Fibra-Cel*, cjelokupni sustav je ispražnjen od tekućine, a tada je napunjen s vodom za injektiranje (WFI).
The organic solution was then washed with brine and dried over sodium sulfate before evaporating to dryness. 
Organska otopina je bila tada isprana sa slanom vodom i osušena na natrijevom sulfatu prije uparavanja do suhoće.
Collagenase for use according to Claim 6 or claim 7, wherein after one month of receiving at least one administration of collagenase, the patient achieves an active external rotation of greater than 15º, as compared to baseline. 
Kolagenaza za uporabu prema zahtjevu 6 ili zahtjevu 7, naznačena time da nakon jednog mjeseca primanja najmanje jednog davanja kolagenaze, pacijent postiže aktivnu vanjsku rotaciju veću od 15", u usporedbi s početnim stanjem.
The compound of claim 1, wherein the compound of Formula I is represented a compound selected from the group consisting of: 
Spoj iz patentnog zahtjeva 1, gdje se spoj odabran iz grupe sastoji od:
The method according to claim 1 wherein the steel parts are dried, after immersion in the flux solution, at 60-120° C. for a maximum time of 60 minutes. 
Postupak u skladu s patentnim zahtjevom 1 pri čemu su čelični dijelovi osušeni, nakon uranjanja u otopinu fluksa, na 60-120%C kroz vrijeme od najviše 60 minuta.
A process for preparing a free or microencapsulated highly bsh active bacteria comprising growing bsh-producing bacteria in media comprising a carbon source, a nitrogen source, and a pH of 4 to 7 and harvesting the bacteria after 12 to 24 hours, optionally 12-16 hours, wherein the carbon source optionally comprises maltose, sucrose, dextrin, a combination of sorbitol and glucose or a combination of inulin and glucose; and wherein the nitrogen source optionally comprises i) yeast extract and malt extract, yeast extract and beef extract, or casein hydrolysate and malt extract; and (ii) peptone, such as peptone no. 
Postupak za pripravu bakterija visoke BSH aktivnosti kako je definirano u patentnom zahtjevu 1 obuhvaća uzgoj bakterija koje stvaraju BSH u mediju koji sadrži izvor ugljika, izvor dušika i pH od 4 do 7 i ubiranje bakterija nakon 12 do 24 sata, opcionalno 12-16 sati, pri čemu medij nadalje sadrži cistein; pri čemu izvor ugljika sadrži maltozu, sukrozu, dekstrin, kombinaciju sorbitola i glukoze, ili kombinaciju inulina i glukoze; i pri čemu izvor dušika sadrži (1) ekstrakt kvasca 1 ekstrat slada, ekstrakt kvasca 1 goveđi ekstrakt ili hidrolizat kazeina i ekstrakt slada; 1 (11) pepton, opcionalno pepton br.
Direct compression process: The dihydrogenphosphate salt monohydrate was formulated into a tablet by a direct compression process. 
Monohidrat dihidrogenfosfatne soli je formuliran u tabletu direktnim kompresijskim postupkom.
The process of claim 1, wherein said PSA unit adsorbs at a temperature of at least 150 °C and a pressure of at least 5516 kPa (800 psia). 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što navedeni PSA adsorbira na temperaturi od najmanje 150 *C i pod tlakom od najmanje 5516 kPa (800 ps1a).
Results of these assays are given in Table 2 below. 
Rezultati ovih pokusa dati su u Tabeli 2 ispod.
The use of a glitazone in the preparation of a medicament for the treatment of inflammatory respiratory disease by pulmonary administration by inhalation wherein the glitazone content of the medicament consists of at least 95% by weight of the 5R configuration and less than 5% by weight of the 5S configuration, and wherein the said glitazone is pioglitazone or rosiglitazone. 
Uporaba glitazona za dobivanje lijeka za liječenje upalne respiratorne bolesti pulmonalnom administracijom sa inhalacijom naznačena time da se sadržaj glitazona u lijeku sastoji od barem 95% težinski SR konfiguracije i manje od 5% težinski 55 konfiguracije, te pri čemu navedeni glitazon je pioglitazon ili rosiglitazon.
The monodisperse composition of claim 1 or claim 2, wherein the composition is administered at a dose of 0.001 mg to 100 mg. The monodisperse composition of claim 1 or claim 2, wherein the compound is selected from the group consisting of a,B-6-CH3-(OCH2CH2)5-O-naloxol; 
Monodisperzna smjesa iz zahtjeva 1, naznačena time, što se spoj bira iz grupe koja sadrži 0,B-6-CH3-Â«(OCH2CH2)5-O-naloksol; 0,B-6-CH3-(OCH2CH2)s-O-naloksol; 1 0,B-6-CH3-Â«(OCH2CH2);-O-naloksol; ili farmaceutski prihvatljivu sol istih.
An orally disintegrating tablet comprising less than or equal to about 20 mg of a corticosteroid selected from the group consisting of fluticasone, budesonide, mometasone, and salts, solvates and esters thereof, and at least one disintegrant, wherein the orally disintegrating tablet disintegrates within 60 seconds when tested using the USP <701> Disintegration Test. 
Tableta za oralno disperziranje sukladno patentnom zahtjevu 6, koja sadrži manje ili jednako 20 mg budezonida ili njegovog solvata ili estera, i najmanje jedno sredstvo za raspršivanje, pri čemu se tableta razgrađuje unutar 60 sekundi u simuliranoj tekućini sline kada se testiranje provodi uporabom USP <701> Testa razgradnje.
A compound as claimed in claim 20 or claim 21 wherein ring A is (i) optionally substituted phenyl, wherein optional substituents are selected from C1-C3alkoxy, halo, C1-C3-alkyl, amino C1-C3-acyl, and amino C1-C3-alkyl, or (ii) a phenyl-fused-heterocycloalkyl ring system wherein the heterocycloalkyl ring is a monocyclic heterocyclic ring of 5 or 6 ring atoms. 
Spoj prema zahtjevu 20 ili zahtjevu 21 naznačen time da prsten A je (i) opcijski supstituiran fenil, pri čemu su opcijski supstituenti odabrani od C1-C3alkoksi, halo, C1-C3-alkil, amino C1-C3-acil, i amino C1-C3-alkil, ili (ii) fenil-fuzionirani-heterocikloalkilni sustav prstena pri čemu je heterocikloalkilni prsten monociklički heterociklički prsten sa 5 ili 6 atoma u prstenu.
Preferably, a rising gas stream is generated in the cyclone tower wherein the fibre cement material is dispersed in said dry powdered form. In practice a rising gas stream is generated in the cyclone tower by means of one or more induced draft fans (ID fans) provided at the top of the cyclone tower. 
Postupak prema patentnom zahtjevu 3, naznačen time što se u ciklonskom tornju (11) generira uzlazna struja plina, pri čemu je materijal od vlaknastog cementa dispergiran u navedenom suhom praškastom obliku.
A composition according to claim 7 wherein said second antibody comprises an antigen binding domain comprising a variable heavy domain comprising SEQ ID NO:5 and a variable light domain comprising SEQ ID NO:10. 
Pripravak prema zahtjevu 7, naznačen time što navedeno drugo antitijelo sadrži domenu vezanu antigenom, koja sadrži varijabilnu tešku domenu koja sadrži SEQ ID NO: 5 i varijabilnu laku domenu koja sadrži SEQ ID NO: 10.
Method according to the claim 17 where the mixing of composition based on tin tetrachloride anhydrous and the air takes place in the exit (5) of the mixer (2). 
Metoda prema patentnom zahtjevu 17 gdje se miješanje kompozicije bazirane na bezvodnom kositar tetrakloridu 1 zraka odvija na izlazu (5) miješalice (2).
The method of Claim 6, wherein the image is output (38) on a contact lens operable to be placed (40) on the eye. 
Postupak prema zahtjevu 5, naznačen time, da slika izlazi (38) na kontaktnu leću pripremljenu za operaciju postavljanja (40) na oko.